<DOC>
	<DOCNO>NCT01173562</DOCNO>
	<brief_summary>The purpose study assess safety tolerability mebendazole 500-mg chewable tablet formulation pediatric population . Mebendazole drug use treatment soil-transmitted parasitic helminth ( STH ) ( ie , parasitic worm ) infection pinworm , whipworm , common roundworm , common hookworm , American hookworm .</brief_summary>
	<brief_title>A Safety Study Mebendazole Children 2 10 Years Age</brief_title>
	<detailed_description>This open-label ( identity study drug know study participant investigator ) , single-center , single-dose , single-arm ( ie , 1 treatment group ) safety study . This study consist screen visit Day 1 time study-related screening procedure perform . After result review , child meet inclusion criterion none exclusion criterion enter open-label phase study . A single mebendazole 500-mg chewable tablet administer Day 1 child remain study site adverse event record approximately 30 minute postdose . Study participant return study site 3 day ( plus minus 1 day ) postdose time adverse event record . Safety monitor study assess adverse event direct observation 30 minute dose 3 day ( plus minus 1 day ) dosing , direct observation study participant , report parent guardian , . On Day 1 , single mebendazole 500-mg chewable tablet chew swallow study participant . If desire , study participant allow drink water administer study drug .</detailed_description>
	<mesh_term>Mebendazole</mesh_term>
	<mesh_term>Piperazine</mesh_term>
	<mesh_term>Piperazine citrate</mesh_term>
	<criteria>Be otherwise healthy child base medical history , physical examination , vital sign , concomitant medication live highprevalence area parasite infection endemic ( ie , Prevalent peculiar particular locality , region , people ) Have teeth able chew mebendazole chewable tablet Girls must premenarchal Parent ( ) /guardians study participant ( legallyaccepted representative ) must sign informed consent document indicate understand purpose procedure require study willing child participate study Have history clinically significant liver renal insufficiency cardiac , vascular , pulmonary , gastrointestinal , endocrine , neurologic , hematologic ( eg , anemia ) , rheumatologic , psychiatric , metabolic disturbance , opinion investigator , render candidate suitable mebendazole treatment Have suspect massive intestinal parasitic infection , base history physical finding , determine principal investigator Have condition , opinion investigator , would compromise wellbeing study participant study prevent study participant meeting perform study requirement</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>10 Years</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>Healthy volunteer</keyword>
	<keyword>Parasitic Diseases</keyword>
	<keyword>Mebendazole ( VERMOX )</keyword>
	<keyword>Anthelmintics</keyword>
	<keyword>Antiparasitic Agents</keyword>
	<keyword>Soil-transmitted helminth ( STH ) infection</keyword>
	<keyword>Pediatric</keyword>
</DOC>